Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

WUN 2026 National Summit Schedule Released

Registration NOW OPEN – 2026 Wake Up Narcolepsy Family Weekend

2025 Wake Up Narcolepsy Special Research Update

Wake Up Narcolepsy Featured in 2025 “My Cause My Cleats” NFL Campaign by Nazir Stackhouse

Register now for WUN’s 2026 National Summit

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

2025 WUN Town Halls Wrap Up

Future Neurology “Experiences of people with narcolepsy who switched from sodium oxybate to low-sodium oxybate: a plain language summary”

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence